Immix Biopharma - CAR-T trial moves to US with outpatient potential
⬆ $Immix Biopharma Inc(IMMX)$ - The FDA has accepted Immix’s Investigational New Drug (IND) application for lead CAR-T asset NXC-201. In our view, this decision from the FDA...
Continue reading on Smartkarma:- https://www.smartkarma.com/insights/immix-biopharma-car-t-trial-moves-to-us-with-outpatient-potential?utm_source=tiger_community
By Edison Investment Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/edison-investment-research?utm_source=tiger_community
On Immix Biopharma Inc (IMMX):- https://www.smartkarma.com/entities/immix-biopharma-inc?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
